
    
      After being informed about the study and potential risks, all patients will give written
      informed consent and undergo a 1 day screening period to determine the eligibility for study
      entry. At day 0, patients who meet the eligibility requirements will be randomized in a
      double blind (participant and investigator) in a 1:1 ratio to metformin glycinate (620 mg,
      taken orally twice daily) plus standard treatment or placebo (taken orally,twice daily) plus
      standard treatment, both will be for 14 days.
    
  